| Rheumatic Disease | Study (Study Name) | Biosimilar (n) Product [Switch Group] / Biologic Reference Product (n) [Control Group] |
Post-Switch Follow-up Duration, wk | Patients Discontinuing Treatment, n (%) (Switch vs. Control Group) |
| RA | Cohen et al. 2018 [54] (VOLTAIRE-RA) |
BI695501 (n=147) / adalimumab (n=147) | 24-34 | 9 (6%) vs. 8 (5%) |
| Genovese 2017 [55] (ARABESC-OLE) |
FKB327 (n=108) / adalimumab (n=213) | 76 | NR | |
| Weinblatt et al. 2017 [56] | SB5 (n=125) / adalimumab (n=129) | 28 | 8 (6%) vs. 5 (4%) | |
| Cohen et al. 2017 [57, 58] | ABP 501 (n=237) / adalimumab (n=229) | 46 | 30 (13%) vs. 25 (11%) | |
| Emery et al. 2017 [59] | SB4 (n=119) / etanercept (n=126) | 48 | 6 (5%) vs. 7 (6%) | |
| Smolen et al. 2018 [31] | SB2 (n=94) / infliximab (n=101) | 16 | 6 (6%) vs. 5 (5%) | |
| Tanaka et al. 2017 [60] | CT-P13 (n=33) / infliximab (n=38) | 105 | 11 (33%) vs. 6 (16%) | |
| Yoo et al. 2017 [61] (PLANETRA) |
CT-P13 (n=144) / infliximab (n=158) | 48 | 16 (11%) vs. 25 (16%) | |
| Taylor et al. 2016 [62] | BOW015 (n=53) / infliximab (n=104) | 38 | NR | |
| AS | Park et al. 2017 [63] (PLANETAS) |
CT-P13 (n=86) / infliximab (n=88) | 48 | 9 (10%) vs. 7 (8%) |
| Ps ± PsA | Blauvelt et al. 2017 [64] (ADACCESS) |
GP2017 (n=63) / adalimumab (n=127) | 34 | 16 (25%) vs. 23 (18%) |
| Hodge et al. 2017 [65] | CHS-1420 (n=124) / adalimumab (n=129) | 8 | NR | |
| Papp et al. 2017 [66] | ABP 501 (n=77) / adalimumab (n=79) | 36 | 9 (12%) vs. 8 (10%) | |
| Griffiths et al. 2017 [32, 67] (EGALITY) |
GP2015 (n=96) / etanercept (n=151) | 40 | 6 (6%) vs. 14 (9%) | |
| CD, UC, RA, Ps, PsA, SpA | Jørgensen et al. 2017 [68, 69] (NOR-SWITCH) |
CT-P13 (n=240) / infliximab (n=241) | 78 | 18 (8%) vs. 25 (10%) |
| IBD/CD | Volkers et al. 2017 [70] (SIMILAR) |
CT-P13 (n=15) / infliximab (n=6) | 30 | NR |
| Ye et al. 2018 [71, 72] | CT-P13 (n=55) / infliximab (n=54) | 24 | NR |